Proposed AstraZeneca Anticlotting Drug Better Than Plavix:Study
The Wall Street Journal
An experimental anticlotting drug being developed by AstraZeneca PLC (AZN, AZN.LN) was more effective than the widely used Plavix when used before and after a procedure to open a blocked coronary artery in patients suffering a heart attack, according a new analysis scheduled to be released Sunday.
The drug, with a generic name of ticagrelor, like the market leader Plavix is designed to keep blood platelets from sticking together in order to prevent blood clots that can lead to heart attacks and strokes.
AstraZeneca plans to file an application seeking U.S. ...